Johns Hopkins Medicine and the University of Maryland Medical System are operating an outpatient center to provide infusion therapy for patients with COVID-19. Located at the Baltimore Convention Center, the infusion center administers monoclonal antibody therapies authorized by the U.S. Food and Drug Administration (FDA) under an emergency use authorization (EUA). Referrals are required. Monoclonal antibody therapy helps prevent hospitalization or worsening of symptoms in certain patients with COVID-19, but it may not be appropriate for everyone.
These therapies include:
- Bamlanivimab (manufactured by Eli Lilly & Co.)
- A combination of casirivimab and imdevimab, administered simultaneously (known as Regeneron)
The Baltimore Convention Center COVID-19 Infusion Center is open Monday through Saturday, 8 a.m.– 6 p.m.
For Referring Providers – Baltimore Convention Center
- To refer a patient for treatment to the Baltimore Convention Center COVID Infusion Center, outpatient providers should complete this Infusion Center online referral form.
The Baltimore Convention Center infusion suite team will review the referral form upon receipt and contact the patient to coordinate services as soon as possible.
The infusion combination therapy, casirivimab and imdevimab, acts similarly to bamlanivimab, with similar inclusion and exclusion criteria. This combination therapy is not offered at our site at this time, but it may be offered in the near future. Both treatments have the same FDA EUA criteria, and have been demonstrated to reduce COVID-19 hospitalization or emergency room visits when administered within 10 days of symptom onset.
Therapy must be ordered for the treatment of mild to moderate COVID-19 in adults and pediatric patients who have positive results of direct SARS-CoV-2 viral testing, are 12 years of age and older, weigh at least 40 kilograms, and are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as patients who meet at least one of the following criteria:
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have cardiovascular disease, OR hypertension, OR chronic obstructive pulmonary disease/other chronic respiratory disease
- Are 12–17 years of age AND have a BMI ≥85th percentile for their age and gender based on CDC growth charts: cdc.gov/growthcharts/clinical_charts.htm; OR sickle cell disease; OR congenital or acquired heart disease; OR neurodevelopmental disorders, such as cerebral palsy; OR a medical-related technological dependence, such as tracheostomy gastrostomy or positive pressure ventilation (not related to COVID-19); OR asthma, reactive airway disease or other chronic respiratory disease that requires daily medication for control
These therapies are not authorized for use in patients who:
- Are hospitalized due to COVID-19
- Require oxygen therapy due to COVID-19
- Require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to an underlying non-COVID-19-related comorbidity
The allocation methodology is based on duration of symptom onset (longest to be prioritized). There is no further risk stratification based on other clinical characteristics at this point. Which treatment is administered will be decided based on availability and logistics.
There is a chance that a patient’s clinical condition may change in the time between referral and arrival at the infusion center, and the patient may no longer be eligible for this treatment. We urge providers to discuss this with patients, and help manage their expectations.
Referring providers should reference these provider fact sheets:
*The infusion center at the Baltimore Convention Center is jointly operated by Johns Hopkins Medicine and University of Maryland Medical System. The University of Maryland Medical Center’s COVID-19 infusion center website is umms.org/InfusionCenter.